A blood test that could look for several cancers at once sounds like something from the future. No complicated preparation. No appointment that requires an entire afternoon. Just a blood draw and, potentially, information about what is happening inside your body. It’s easy to see the appeal. But can a blood test really detect cancer before symptoms appear?
The short answer: Some newer blood tests can detect signals associated with multiple cancers, sometimes before symptoms appear. But they miss many cancers, and researchers have not yet established that adding them to routine screening saves lives. They are promising tools, not replacements for mammograms, colonoscopies, or other recommended screening tests.
What is a multi-cancer early detection blood test?
A multi-cancer early detection (MCED) test searches a blood sample for biological clues that may come from cancer. One approach examines tiny fragments of DNA floating in the bloodstream, called cell-free DNA. The Galleri test looks at chemical patterns on that DNA, known as methylation, to identify signals associated with cancer. Think of methylation as a set of molecular annotations. Researchers use those patterns to help distinguish signals associated with tumors from signals produced by healthy cells.
A positive result is not a cancer diagnosis. It means a clinician needs to investigate your health more closely, potentially with imaging, laboratory tests, or a biopsy. And a negative result cannot rule cancer out. That distinction is the difference between a helpful clue and a definitive answer.
What did the largest trial actually find?
In September 2026, researchers published results from the NHS-Galleri trial in the New England Journal of Medicine. More than 142,000 adults ages 50–77 in England were randomly assigned to receive three annual rounds of MCED testing plus usual care, or usual care without receiving MCED results. The key question was whether adding the test reduced diagnoses of stage III or IV cancers across 12 specified cancer types.[1]
The result was sobering: the trial did not find a statistically significant reduction in stage III and IV diagnoses combined, its primary endpoint. There was a signal suggesting fewer stage IV diagnoses, but that secondary finding does not erase the primary result. Longer follow-up will help clarify what these changes mean.[1]
In plain English? Finding more cancers early sounds wonderful, but the most important question is whether screening meaningfully changes what happens to people. That requires more evidence than a test finding an abnormal signal.
How accurate are these blood tests?
Another study published in Nature Medicine in September 2026, PATHFINDER 2, examined Galleri testing in adults ages 50 and older in the United States and Canada. The reported specificity was about 99.6%, meaning the test rarely returned a positive signal among people without a cancer diagnosis during the study’s evaluation period. But its overall sensitivity was about 39%, meaning many cancers diagnosed within the follow-up period were not detected by the test.[2]
That is a surprisingly important pairing. A test can be very good at avoiding false alarms and still miss many cases. Results also differ by cancer type and stage. The PATHFINDER 2 study did not randomly compare screened and unscreened groups, so it could not demonstrate a reduction in cancer deaths.[2]
A separate Nature Medicine analysis of the NHS trial examined performance across three annual screening rounds. It showed that test sensitivity varied across rounds, reinforcing why a negative result should never be treated as an all-clear.[3]
Could a blood test replace my mammogram or Pap smear?
No. Current MCED tests are intended to complement—not replace—established screening. A mammogram looks for breast changes using imaging. Cervical screening checks for HPV or abnormal cervical cells. Colorectal screening uses stool-based tests or direct examination of the colon. Each method is designed for a particular job. A multi-cancer blood test does something different, and its ability to identify a signal does not make the other tests optional.[4]
What should women over 40 do now?
First, check whether you are up to date on recommended breast, cervical, and colorectal screening. The right schedule depends on your age, previous results, family history, and other risk factors. Second, tell your clinician about close relatives who have had cancer; that information can change screening recommendations. Third, never ignore new or persistent symptoms because a blood test was negative. Fourth, if you are considering an MCED test, ask what a positive result would trigger, what follow-up might cost, and what a negative result cannot tell you.
You don’t need to become your own full-time medical researcher. (Your calendar probably has enough meetings already.) The useful habit is simpler: Keep a record of your screenings and make space for a thoughtful conversation with your healthcare professional.
What comes next for cancer-detection blood tests?
Scientists are studying whether repeated testing, better algorithms, and longer follow-up will make these tools more useful. For now, the most encouraging part of the story is not that one blood test has solved cancer screening. It is that researchers are rigorously testing a new idea—and reporting where it falls short as well as where it succeeds.
Curiosity is good. Staying current on proven screening is even better. Your next best step is to ask your clinician which cancer screenings belong on your calendar this year.
Educational information only; not medical advice or a substitute for individualized screening recommendations.